Bridgeway Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Bridgeway Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,533	Closed	-$103K	–	1430
2019 Q1	$103K	Sell	10,533 -1,667	-14%	-$18.4K	﹤0.01%	1278
2018 Q4	$147K	Buy	12,200 +4,000	+49%	+$58.1K	﹤0.01%	1258
2018 Q3	$133K	Hold	8,200	–	–	﹤0.01%	1362
2018 Q2	$298K	Buy	8,200 +6,667	+435%	+$231K	﹤0.01%	1251
2018 Q1	$48K	Hold	1,533	–	–	﹤0.01%	1362
2017 Q4	$59K	Buy	+1,533	New	+$40.2K	﹤0.01%	1364
2016 Q2	–	Sell	-6,667	Closed	-$246K	–	1496
2016 Q1	$246K	Hold	6,667	–	–	﹤0.01%	1262
2015 Q4	$296K	Buy	+6,667	New	+$323K	0.01%	1204

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bridgeway Capital Management's BLPH Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2019, closing a stake of 10,533 shares — an estimated $103K sold.

Bridgeway Capital Management first reported a position in BLPH in Q4 2015 and held it in 8 quarters. The position peaked at $298K in Q2 2018. 26 funds tracked by Wall St. Rank hold BLPH as of Q2 2019.

Bridgeway Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 10,533 Bellerophon Therapeutics, Inc. shares in Q2 2019, an estimated $103K.
Bridgeway Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q4 2015 and held it in 8 quarters.
Bridgeway Capital Management's Bellerophon Therapeutics, Inc. position peaked at $298K in Q2 2018.
26 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.